Angelman Syndrome Biomarker & Outcome Measure Consortium (ABOM): Understanding What Matters to Patients with a Heterogenous Neurodevelopmental Disorder

Time: 4:30 pm
day: Day One

Details:

• NHS, Disease concept models and focus domains on what is important to patients and caregivers: Staying pre-competitive

Speakers: